START-R, START-C: Dasatinib in the treatment of CML-CP

April 2008
Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p9
The article discusses the outcomes of the START-R and START-C studies involving patients with chronic phase chronic myeloid leukemia who are resistant to standard dose imatinib. It references a study by H. M. Kantajian and colleagues, and a study by R. M. Stone and colleagues, both presented at the 2007 annual meeting of the American Society of Hematology. The studies have found that dasatinib have produced higher rates of cytogenetic and major molecular responses, as well as superior progression-free survival over imatinib therapy.


Related Articles

  • Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Shah, Neil P. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p49 

    The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • imatinib.  // Royal Society of Medicine: Medicines;2002, p297 

    This article provides information on the drug imatinib. It is a recently introduced protein-tyrosine kinase inhibitor cytotoxic drug, which is used as an anticancer treatment for myeloid leukemia. It works by interference with the action of an abnormal form of an enzyme in the body that can...

  • Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. O'Brien, S. G.; Meinhardt, P.; Bond, E.; Beck, J.; Peng, B.; Dutreix, C.; Mehring, G.; milosavljev, S.; Huber, C.; Capdeville, R.; Fischer, T. // British Journal of Cancer;11/17/2003, Vol. 89 Issue 10, p1855 

    The inhibition by imatinib of the cytochrome P450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clinically important coadministered drugs. The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a...

  • Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Breccia, Massimo; Russo, Eleonora; De Propris, Maria Stefania; Frustaci, Annamaria; Alimena, Giuliana // Acta Haematologica;Oct2006, Vol. 116 Issue 3, p211 

    The article describes two cases of chronic myeloid leukemia (CML) treated with imatinib mesylate on the basis of the bright expression of c-kit on blast cells. The first case involves a 53-year-old woman who was admitted to a hospital due to itchiness and splenomegaly. The second case involves a...

  • Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Hochhaus, A; La Rosée, P. // Leukemia (08876924);Aug2004, Vol. 18 Issue 8, p1321 

    Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia (CML). Selective inhibition of BCR-ABL activity by imatinib has demonstrated efficacy in the treatment of CML,...

  • Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Burchert, A.; Wang, Y.; Cai, D.; von Bubnoff, N.; Paschka, P.; Müller-Brüsselbach, S.; Ottmann, O. G.; Duyster, J.; Hochhaus, A.; Neubauer, A. // Leukemia (08876924);Oct2005, Vol. 19 Issue 10, p1774 

    BCR/ABL-kinase mutations frequently mediate clinical resistance to the selective tyrosine kinase inhibitor Imatinib mesylate (IM, Gleevec®). However, mechanisms that promote survival of BCR/ABL-positive cells before clinically overt IM resistance occurs have poorly been defined so far. Here,...

  • Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Shah, Neil P.; Skaggs, Brian J.; Branford, Susan; Hughes, Timothy P.; Nicoll, John M.; Paquette, Ronald L.; Sawyers, Charles L. // Journal of Clinical Investigation;Sep2007, Vol. 117 Issue 9, p2562 

    Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously. We addressed the potential long-term impact of this strategy in patients with chronic myelogenous leukemia (CML), which is driven by the fusion oncogene BCR-ABL. Analysis of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics